



# Maple-Brown Abbott Australian Value Opportunities Fund

Monthly Commentary – 31 March 2024

## Fund performance (%) <sup>1</sup>

	1 month	3 months	1 year	Since inception p.a. 01 Apr 2021
Fund <sup>2</sup>	5.3	9.2	15.1	12.3
Reference Benchmark <sup>3</sup>	3.3	5.4	14.4	9.4

## Market commentary

The Australian equity market had a strong month, with the S&P/ASX 300 Total Return Index rising 3.3%. Performance was in line with global markets, driven by hopes of a soft landing in the US. Bond yields softened somewhat, with the US 10-year Government yield falling 0.04% to 4.2% and the Australian 10-year down 0.17% to 3.97%. Local economic data showed a slowing economy, with anaemic Q4 GDP growth and subdued retail sales. Commodity markets were mixed, with gains in oil and weaker iron ore the key price moves. Looking at performance by sector, A-REITs (+10%) was best, followed by Energy (+6%) and Utilities (+5%). Communication Services (-1%) was weakest, followed by Consumer Discretionary (+1%) and Health Care (+2%).

## Portfolio commentary

The Fund returned 5.3% over the month, outperforming the reference benchmark by 2.0%.

Our holding in Alumina (+35%) was a key positive contributor. Sentiment has been improving since the approval of its mine plan in December and the scrip-funded takeover proposal from joint-venture partner Alcoa Inc. in February has further supported the stock. With Alumina signing an Implementation Deed in March, the stock now trades in lockstep with its suitor Alcoa and performance over the month benefited from aluminium sector tailwinds. Our holding in Virgin Money UK (+35%) was another positive, with the company receiving a

takeover offer from Nationwide Building Society during the month. The offer of 220 pence in cash represented a 38% premium to the last closing price and has received the support of the Virgin board. Our holding in ResMed Inc (+13%) performed strongly. The stock was supported by easing concerns around the impact of GLP-1 weight loss drugs and the market re-entry of competitor Phillips on demand for its sleep apnoea devices. Our holdings in energy producers Santos (+10%) and Beach energy (+15%) also contributed positively, supported by strength in energy prices and in the case of Beach the announcement of a strategic review and cost reduction program.

Our holding in McMillan Shakespeare (-7%) detracted from performance. The stock retraced some of its recent gains, with government moves to reform the NDIS also creating some uncertainty around its plan management division. The core salary packaging and novated lease business is performing very well, however, with tax incentives for electric vehicles purchased using a novated lease driving strong demand. Our position in Westpac Banking Corp (-1%) contributed negatively. It lagged the broader banking sector, releasing an underwhelming strategic update detailing elevated spending for a technology simplification program over the next four years. Our holding in G8 Education (-3%) also detracted. The company announced the settlement of a class action brought by shareholders claiming a breach of continuous disclosure obligations relating to an earnings downgrade in 2017. While G8 has not admitted fault, the settlement is expected to have a cash cost of \$25m.

Please see next page for Outlook

### Notes:

<sup>1</sup> Past performance is not a reliable indicator of future performance. Source: Maple-Brown Abbott Ltd, S&P as at 31 March 2024.

<sup>2</sup> The Fund's performance is based on the movement in net asset value per unit plus distributions and is before tax and after all fees and charges. Imputation credits are not included in the performance figures.

<sup>3</sup> The reference benchmark is S&P/ASX 300 Total Return Index.

## Want to find out more?

Contact our Client Service team by:

T 1300 097 995

E [mba@unitregistry.com.au](mailto:mba@unitregistry.com.au)

W [maple-brownabbott.com](http://maple-brownabbott.com)

Signatory of:



# Maple-Brown Abbott Australian Value Opportunities Fund

Monthly Commentary – 31 March 2024

## Outlook

Markets remain volatile and, despite some positive signs, there is significant uncertainty around the global macroeconomic outlook, including for inflation, interest rates and growth. We remain cautious that markets are not pricing in these risks, seemingly assuming both a moderation in interest rates and continued solid economic growth.

We observe that many defensives now offer attractive valuations and offer some protection against economic and equity market uncertainties. We continue to see appeal in the energy sector and certain resources, given discounted valuations, strong balance sheets and the likelihood of some protection from inflation. Underperformance of select industrials has also presented opportunities. That said, we observe that valuations of many key stocks in sectors including health care and information technology are stretched and we expect they will deliver disappointing returns. We expect this to support our relative performance.

For latest Fund factsheet [click here](#).

## Disclaimer

This document is prepared and issued by Maple-Brown Abbott Limited ABN 73 001 208 564, AFSL 237296 ("MBA"). It does not constitute advice of any kind and should not be relied upon as such. This document must not be reproduced or transmitted in any form without the prior written consent of MBA. This document does not constitute investment advice or an investment recommendation of any kind and should not be relied upon as such. This document contains general information only, and does not take into account your investment objectives, financial situation or specific needs. Before making any investment decision, you should seek independent investment, legal, tax, accounting or other professional advice as appropriate. This document does not constitute an offer or solicitation by anyone in any jurisdiction. This document is not an advertisement and is not directed at any person in any jurisdiction where the publication or availability of the information is prohibited or restricted by law. Past performance is not a reliable indicator of future performance. Neither MBA, nor any of its related parties, directors or employees, make any representation or give any guarantee as to the return of capital, performance, any specific rate of return, or the taxation consequences of, any investment. Any comments about investments are not a recommendation to buy, sell or hold. Any views expressed on individual stocks or other investments, or any forecasts or estimates, are not a recommendation to buy, sell or hold, they are point in time views and may be based on certain assumptions and qualifications not set out in part or in full in this document. The views and opinions contained in this document are those of the authors as at the date of publication and are subject to change due to market and other conditions. Such views and opinions may not necessarily represent those expressed or reflected in other MBA communications, strategies or funds. Information derived from sources is believed to be accurate, however such information has not been independently verified and may be subject to assumptions and qualifications compiled by the relevant source and this document does not purport to provide a complete description of all or any such assumptions and qualifications. To the extent permitted by law, neither MBA, nor any of its related parties, directors or employees, make any representation or warranty as to the accuracy, completeness, reasonableness or reliability of this information, or accept liability or responsibility for any losses, whether direct, indirect or consequential, relating to, or arising from, the use or reliance on this information. Units in the Fund are issued by MBA. Before making a decision whether to acquire, or to continue to hold an investment in the Fund, you should obtain and consider the current Product Disclosure Statement, Additional Information Booklet and Target Market Determination for the Fund issued by MBA and available at [maple-brownabbott.com/document-library](http://maple-brownabbott.com/document-library) or by calling 1300 097 995. An investment in the Fund does not represent an investment in, deposit with or other liability of MBA, and is subject to investment risk including possible delays in repayment and loss of income and principal invested. This information is current as at 31 March 2024 and is subject to change at any time without notice.

## Want to find out more?

Contact our Client Service team by:

T 1300 097 995

E [mba@unitregistry.com.au](mailto:mba@unitregistry.com.au)

W [maple-brownabbott.com](http://maple-brownabbott.com)

Signatory of:

